Literature DB >> 26309369

Robotic radiosurgery in pancreatic cancer: A systematic review.

Milly Buwenge1, Francesco Cellini1, Nicola Silvestris1, Savino Cilla1, Francesco Deodato1, Gabriella Macchia1, Gian C Mattiucci1, Vincenzo Valentini1, Alessio G Morganti1.   

Abstract

AIM: To present a systematic review of techniques and clinical results.
METHODS: A systematic review of published literature was performed. Only studies reporting patient outcome after radiosurgery (single fraction) delivered with robotic devices [i.e., robotic radiosurgery (RRS)] have been analyzed.
RESULTS: A total of 96 patients from 5 studies were included. The studies are characterized by small series and different methods in terms of dose, target definition, combination with chemotherapy and/or standard fractionated radiotherapy and evaluation modalities. Preliminary results are positive in terms of tumor response (ORR = 56%) and local control of the tumor (crude rate of local progressions: 19.5%). Results for median overall survival (11.4 mo) seem comparable with the ones of prolonged chemoradiation (range: 8.6-13.0 mo). However, gastrointestinal toxicity seems to be the main limitation of RRS, especially at the duodenal level.
CONCLUSION: RRS allows for local treatment in a shortened time (1 fraction) compared to traditional treatments (about 1 mo), providing the possibility for an easy integration with systemic therapies. Preliminary results did not show any outcome differences compared to standard chemoradiation. Thus, further efforts to reduce gastrointestinal toxicity are strongly needed.

Entities:  

Keywords:  Pancreas; Pancreatic neoplasms; Radiosurgery; Review; Robotic; Stereotactic radiotherapy; Systematic review

Mesh:

Year:  2015        PMID: 26309369      PMCID: PMC4541395          DOI: 10.3748/wjg.v21.i31.9420

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  48 in total

1.  Stereotactic body radiation therapy for nonresectable tumors of the pancreas.

Authors:  Kush Goyal; Douglas Einstein; Rafael A Ibarra; Min Yao; Charles Kunos; Rod Ellis; James Brindle; Deepjot Singh; Jeffrey Hardacre; Yuxia Zhang; Jeffrey Fabians; Gary Funkhouser; Mitchell Machtay; Juan R Sanabria
Journal:  J Surg Res       Date:  2011-09-05       Impact factor: 2.192

2.  FOLFIRINOX in locally advanced pancreatic cancer: the Massachusetts General Hospital Cancer Center experience.

Authors:  Jason E Faris; Lawrence S Blaszkowsky; Shaunagh McDermott; Alexander R Guimaraes; Jackie Szymonifka; Mai Anh Huynh; Cristina R Ferrone; Jennifer A Wargo; Jill N Allen; Lauren E Dias; Eunice L Kwak; Keith D Lillemoe; Sarah P Thayer; Janet E Murphy; Andrew X Zhu; Dushyant V Sahani; Jennifer Y Wo; Jeffrey W Clark; Carlos Fernandez-del Castillo; David P Ryan; Theodore S Hong
Journal:  Oncologist       Date:  2013-05-08

Review 3.  A systematic review and meta-analysis of survival and surgical outcomes following neoadjuvant chemoradiotherapy for pancreatic cancer.

Authors:  Jerome Martin Laurence; Peter Duy Tran; Kavita Morarji; Guy D Eslick; Vincent Wai To Lam; Charbel Sandroussi
Journal:  J Gastrointest Surg       Date:  2011-09-13       Impact factor: 3.452

4.  Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer.

Authors:  Anand Mahadevan; Rebecca Miksad; Michael Goldstein; Ryan Sullivan; Andrea Bullock; Elizabeth Buchbinder; Douglas Pleskow; Mandeep Sawhney; Tara Kent; Charles Vollmer; Mark Callery
Journal:  Int J Radiat Oncol Biol Phys       Date:  2011-06-12       Impact factor: 7.038

5.  Outcomes with FOLFIRINOX for borderline resectable and locally unresectable pancreatic cancer.

Authors:  Brian A Boone; Jennifer Steve; Alyssa M Krasinskas; Amer H Zureikat; Barry C Lembersky; Michael K Gibson; Ronald G Stoller; Herbert J Zeh; Nathan Bahary
Journal:  J Surg Oncol       Date:  2013-09       Impact factor: 3.454

6.  A phase I/II trial of intensity modulated radiation (IMRT) dose escalation with concurrent fixed-dose rate gemcitabine (FDR-G) in patients with unresectable pancreatic cancer.

Authors:  Edgar Ben-Josef; Mathew Schipper; Isaac R Francis; Scott Hadley; Randall Ten-Haken; Theodore Lawrence; Daniel Normolle; Diane M Simeone; Christopher Sonnenday; Ross Abrams; William Leslie; Gazala Khan; Mark M Zalupski
Journal:  Int J Radiat Oncol Biol Phys       Date:  2012-04-27       Impact factor: 7.038

7.  Adjuvant stereotactic body radiotherapy for resected pancreatic adenocarcinoma with close or positive margins.

Authors:  Jean-Claude M Rwigema; Dwight E Heron; Simul D Parikh; Herbert J Zeh; James A Moser; Nathan Bahary; Karlotta Ashby; Steven A Burton
Journal:  J Gastrointest Cancer       Date:  2012-03

8.  Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated.

Authors:  Michael D Chuong; Gregory M Springett; Jessica M Freilich; Catherine K Park; Jill M Weber; Eric A Mellon; Pamela J Hodul; Mokenge P Malafa; Kenneth L Meredith; Sarah E Hoffe; Ravi Shridhar
Journal:  Int J Radiat Oncol Biol Phys       Date:  2013-04-05       Impact factor: 7.038

9.  Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine.

Authors:  Daniel D Von Hoff; Thomas Ervin; Francis P Arena; E Gabriela Chiorean; Jeffrey Infante; Malcolm Moore; Thomas Seay; Sergei A Tjulandin; Wen Wee Ma; Mansoor N Saleh; Marion Harris; Michele Reni; Scot Dowden; Daniel Laheru; Nathan Bahary; Ramesh K Ramanathan; Josep Tabernero; Manuel Hidalgo; David Goldstein; Eric Van Cutsem; Xinyu Wei; Jose Iglesias; Markus F Renschler
Journal:  N Engl J Med       Date:  2013-10-16       Impact factor: 91.245

10.  Stereotactic body radiation therapy for reirradiation of localized adenocarcinoma of the pancreas.

Authors:  Chris E Lominska; Keith Unger; Nadim M Nasr; Nadim Haddad; Greg Gagnon
Journal:  Radiat Oncol       Date:  2012-05-18       Impact factor: 3.481

View more
  6 in total

1.  Individually optimized stereotactic radiotherapy for pancreatic head tumors: A planning feasibility study.

Authors:  Milly Buwenge; Savino Cilla; Alessandra Guido; Lucia Giaccherini; Gabriella Macchia; Francesco Deodato; Silvia Cammelli; Francesco Cellini; Gian C Mattiucci; Vincenzo Valentini; Markus Stock; Alessio G Morganti
Journal:  Rep Pract Oncol Radiother       Date:  2016-09-28

2.  Impact of Using Unedited CT-Based DIR-Propagated Autocontours on Online ART for Pancreatic SBRT.

Authors:  Alba Magallon-Baro; Maaike T W Milder; Patrick V Granton; Wilhelm den Toom; Joost J Nuyttens; Mischa S Hoogeman
Journal:  Front Oncol       Date:  2022-06-08       Impact factor: 5.738

Review 3.  Stereotactic radiotherapy of pancreatic cancer: a systematic review on pain relief.

Authors:  Milly Buwenge; Gabriella Macchia; Alessandra Arcelli; Rezarta Frakulli; Lorenzo Fuccio; Sara Guerri; Elisa Grassi; Silvia Cammelli; Francesco Cellini; Alessio G Morganti
Journal:  J Pain Res       Date:  2018-10-04       Impact factor: 3.133

Review 4.  Ablative Radiotherapy (ART) for Locally Advanced Pancreatic Cancer (LAPC): Toward a New Paradigm?

Authors:  Nicola Simoni; Gabriella Rossi; Francesco Cellini; Viviana Vitolo; Ester Orlandi; Vincenzo Valentini; Renzo Mazzarotto; Nicola Sverzellati; Nunziata D'Abbiero
Journal:  Life (Basel)       Date:  2022-03-22

Review 5.  Effects of chemoradiotherapy and chemotherapy on survival of patients with locally advanced pancreatic cancer: A meta-analysis of randomized controlled trials.

Authors:  Cuiying Wang; Xiaohua Liu; Xiaohua Wang; Yanlei Wang; Na Cha
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

6.  Automated treatment planning as a dose escalation strategy for stereotactic radiation therapy in pancreatic cancer.

Authors:  Savino Cilla; Anna Ianiro; Carmela Romano; Francesco Deodato; Gabriella Macchia; Pietro Viola; Milly Buwenge; Silvia Cammelli; Antonio Pierro; Vincenzo Valentini; Alessio G Morganti
Journal:  J Appl Clin Med Phys       Date:  2020-10-16       Impact factor: 2.243

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.